Related references
Note: Only part of the references are listed.Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation
Junichi Nakagawa et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2021)
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
Jan Steffel et al.
EUROPACE (2021)
Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
Yan Wang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Development and validation of an ultra-high performance liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of direct oral anticoagulants in human plasma
Yu-Fei Zhang et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)
Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS
Takanori Ikeda et al.
PLOS ONE (2021)
Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people
Aldo P. Maggioni et al.
AMERICAN HEART JOURNAL (2020)
Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing
Min Soo Cho et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Development of an INR for rivaroxaban monitoring using plasma samples from patients
James Zhang et al.
THROMBOSIS RESEARCH (2020)
Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study
Jurij Zdovc et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
Yi-Hsin Chan et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Vitamin K in Chronic Kidney Disease
Mario Cozzolino et al.
NUTRIENTS (2019)
Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery
Dmitry Sychev et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2019)
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians
J. Douxfils et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1)
Shinya Suzuki et al.
DRUG METABOLISM AND PHARMACOKINETICS (2018)
The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation
Hsin-Fu Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation
Hiroaki Shimokawa et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Association between prothrombin time and bleeding in hospitalized patients receiving rivaroxaban
Ashley E. Woodruff et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2018)
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Paul Y. Kwo et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin
I. Gouin-Thibault et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation A Review
John W. Eikelboom et al.
JAMA CARDIOLOGY (2017)
Atrial Fibrillation Epidemiology, Pathophysiology, and Clinical Outcomes
Laila Staerk et al.
CIRCULATION RESEARCH (2017)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation
Yi-Hsin Chan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban
Yoshihisa Nakano et al.
JOURNAL OF CARDIOLOGY (2015)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2014)
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF
I. G. Girgis et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Estimation of linkage disequilibrium and interspecific gene flow in Ficedula flycatchers by a newly developed 50k single-nucleotide polymorphism array
Takeshi Kawakami et al.
MOLECULAR ECOLOGY RESOURCES (2014)
Overview of the coagulation system
Sanjeev Palta et al.
INDIAN JOURNAL OF ANAESTHESIA (2014)
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
The J-ROCKET AF Study: A Matter of Ethnicity or a Matter of Weight?
Masatsugu Hori et al.
CIRCULATION JOURNAL (2013)
Safety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese Patients With Non-Valvular Atrial Fibrillation - Subanalysis of J-ROCKET AF for Patients With Moderate Renal Impairment
Masatsugu Hori et al.
CIRCULATION JOURNAL (2013)
Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients
Masato Kaneko et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation
Takahiko Tanigawa et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
The effect of food on the absorption and pharmacokinetics of rivaroxaban
Jan Stampfuss et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Laboratory assessment of rivaroxaban: a review
Meyer Michel Samama et al.
THROMBOSIS JOURNAL (2013)
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
Xu Steven Xu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
Safe and Effective Variability-A Criterion for Dose Individualization
Nicholas H. G. Holford et al.
THERAPEUTIC DRUG MONITORING (2012)
Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2011)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Mark Jean Gnoth et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities
Lesley A. Stevens et al.
KIDNEY INTERNATIONAL (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
Gregory Y. H. Lip et al.
CHEST (2010)
Vitamins K and D Status in Stages 3-5 Chronic Kidney Disease
Rachel M. Holden et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
Ji Jiang et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
Yu Chen Barrett et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
Xia Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Marker selection for genetic case-control association studies
Fredrik H. Pettersson et al.
NATURE PROTOCOLS (2009)
Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2008)
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
Lars C. Borris et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct factor Xa inhibitors.
Stephanie A. Smith et al.
BLOOD (2007)
How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults
Arif H. Kamal et al.
MAYO CLINIC PROCEEDINGS (2007)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Share Paper
